SCHEDULE 13G/A: Tang Capital Management and Kevin Tang Disclose 9.9% Stake in Bolt Biotherapeutics
Beneficial Ownership Report
Tang Capital Management, LLC and Kevin Tang, along with affiliated entities, have filed an amended Schedule 13G disclosing a combined beneficial ownership of 9.9% in Bolt Biotherapeutics, Inc.'s common stock.
Summary
- Tang Capital Management, LLC (TCM), Kevin Tang, Tang Capital Partners, LP (TCP), and Tang Capital Partners International, LP (TCPI) collectively reported beneficial ownership of 3,812,773 shares of Bolt Biotherapeutics, Inc. common stock.
- This aggregate ownership represents 9.9% of the company's outstanding common stock.
- The percentage is based on 38,339,697 shares of Common Stock outstanding as of March 19, 2025, as reported in Bolt Biotherapeutics' Annual Report on Form 10-K filed on March 24, 2025.
- TCM and Kevin Tang share voting and dispositive power over all 3,812,773 shares.
- TCP beneficially owns 2,145,517 shares, representing 5.6% of the class, with shared voting and dispositive power with TCM and Kevin Tang.
- TCPI beneficially owns 1,667,256 shares, representing 4.3% of the class, with shared voting and dispositive power with TCM and Kevin Tang.
- Tang Capital Partners III, Inc. and Tang Capital Partners IV, Inc. reported 0 shares beneficially owned.
- The filing is an Amendment No. 2 to Schedule 13G, indicating a passive investment purpose, not for changing or influencing control of the issuer, except for activities solely in connection with a nomination under Rule 14a-11.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain information that inherently indicates positive or negative sentiment regarding the company's performance or prospects.
Future Outlook
NA
Industry Context
This filing is a standard disclosure of significant passive ownership by an investment firm in a publicly traded biotechnology company. It reflects an investment position rather than operational or strategic changes within the industry.
Related Party Transactions
- Tang Capital Management, LLC, Kevin Tang, Tang Capital Partners, LP, and Tang Capital Partners International, LP share voting and dispositive power over the reported shares, indicating a coordinated investment strategy among these related entities.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which can influence market perception and potentially provide a degree of stability or interest in the stock.
Key Dates
| Date | Description |
|---|---|
| 2025-03-19 | Date as of which 38,339,697 shares of Common Stock were outstanding, as reported in the Issuer's Annual Report on Form 10-K. |
| 2025-03-24 | Date the Issuer's Annual Report on Form 10-K was filed with the SEC. |
| 2025-03-31 | Date of event which requires filing of this statement. |
| 2025-05-15 | Date of signing and filing of this Schedule 13G Amendment No. 2. |
Keywords
Bolt Biotherapeutics, Tang Capital Management, Kevin Tang, Schedule 13G, Beneficial Ownership, Common Stock, SEC Filing, Institutional Ownership, Investment Firm, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.